Everything below concerns freeze-thaw. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-25. Numbers and descriptions here follow the published literature rather than marketing material.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
== Structure == EF-P is a 21 kDa protein encoded by the efp gene. EF-P consists of three β-barrel domains (I, II and III) and has a L shape tRNA structure. Domain II and III of EF-P are similar to each other. Despite the structural similarity of EF-P with tRNA, studies showed that EF-P does not bind to the ribosome at the classical tRNA binding site, but at the distinct position that is located between the P and E sites.
Commonly used detectors are the flame ionization detector (FID) and the thermal conductivity detector (TCD). While TCDs are beneficial in that they are non-destructive, its low detection limit for most analytes inhibits widespread use. FIDs are sensitive primarily to hydrocarbons, and are more sensitive to them than TCD. FIDs cannot detect water or carbon dioxide which make them ideal for environmental organic analyte analysis. FID is two to three times more sensitive to analyte detection than TCD. The TCD relies on the thermal conductivity of matter passing around a thin wire of tungsten-rhenium with a current traveling through it. In this set up helium or nitrogen serve as the carrier gas because of their relatively high thermal conductivity which keep the filament cool and maintain uniform resistivity and electrical efficiency of the filament. When analyte molecules elute from the column, mixed with carrier gas, the thermal conductivity decreases while there is an increase in filament temperature and resistivity resulting in fluctuations in voltage ultimately causing a detector response. Detector sensitivity is proportional to filament current while it is inversely proportional to the immediate environmental temperature of that detector as well as flow rate of the carrier gas. In a flame ionization detector (FID), electrodes are placed adjacent to a flame fueled by hydrogen / air near the exit of the column, and when carbon containing compounds exit the column they are pyrolyzed by the flame.
By the middle of 1982, the Soviet Union alone maintained major mycological herbaria across 25 research institutions or museums and 11 universities, academies, and institutes, together preserving more than one million fungal specimens, including over 5,000 type specimens. The transition from morphology-based systematics to phylogenetics in the 1980s and 1990s further changed the role of historical collections, as scientists began extracting DNA from specimens collected more than a century earlier. Historical plant herbaria as well as dedicated mycological collections have also yielded valuable fungal and oomycete records when older specimens were re-examined for disease symptoms that were not the original focus of collection.
In liquid chromatography-mass spectrometry (LC-MS), the GC is replaced with a liquid chromatograph. The main difference is that chemical derivatization is not necessary. Applications of LC-MS to MFA, however, are rare. In each case, MS instruments divide a particular isotopomer distribution by its molecular weight. All isotopomers of a particular metabolite that contain the same number of labeled carbon atoms are collected in one peak signal. Because every isotopomer contributes to exactly one peak in the MS spectrum, the percentage value can then be calculated for each peak, yielding the mass isotopomer fraction. For a metabolite with n carbon atoms, n+1 measurements are produced. After normalization, exactly n informative mass isotopomer quantities remain. The drawback to using MS techniques is that for gas chromatography, the sample must be prepared by chemical derivatization in order to obtain molecules with charge. There are numerous compounds used to derivatize samples. N,N-Dimethylformamide dimethyl acetal (DMFDMA) and N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) are two examples of compounds that have been used to derivatize amino acids. In addition, strong isotope effects observed affect the retention time of differently labeled isotopomers in the GC column. Overloading of the GC column also must be prevented. Lastly, the natural abundance of other atoms than carbon also leads to a disturbance in the mass isotopomer spectrum. For example, each oxygen atom in the molecule might also be present as a 17O isotope and as a 18O isotope.
Sources: en.wikipedia.org
=== Acting === Shawn's involvement with theater began in 1970 when he met Andre Gregory, who has since directed several of his plays. As a stage actor, he has appeared mostly in his own plays and other projects with Gregory. He made his film debut in 1979, playing Diane Keaton's ex-husband in Woody Allen's Manhattan and an insurance agent in Bob Fosse's All That Jazz. His best-known film roles include Earl in Strange Invaders (1983) and Mr. Hall in Clueless (1995). After seeing his performance in My Dinner with Andre (1981), casting director Janet Hirshenson was so fond of his delivery of the word "inconceivable" that she cast him as Vizzini in The Princess Bride (1987), for whom the word is a catchphrase. Other roles include Baron Von Westphalen in Southland Tales, Cyrus Rose on Gossip Girl, Marty in Vegas Vacation (1997), and Ezra in The Haunted Mansion (2003).
NASA orders four astronauts of the Crew-12 mission to prepare to evacuate the International Space Station due to an air leak on Russia's Zvezda service module. The order is rescinded two hours later as the air leaks are sealed. Energy Secretary Chris Wright announces a nuclear microreactor developed by Antares Nuclear at the Idaho National Laboratory reached criticality, a milestone for the Trump administration's development of nuclear energy. NBC News reports that the Pentagon raised the threat of Israeli spying on the U.S. to the highest level; Israeli and American officials deny the veracity of the report. June 6 – Iran war: The United States military strikes Iranian coastal radar sites after shooting down Iranian drones launched towards the Strait of Hormuz. Iran responds by launching missiles and drones towards U.S. military facilities in Bahrain and Kuwait. June 7 – In an interview with NBC News' Meet the Press, Trump repeats unsubstantiated claims that the 2020 United States presidential election and ongoing California primary elections were "rigged", and declines to rule out compensation for some people prosecuted over the January 6 United States Capitol attack. Trump walks out after journalist Kristen Welker presses him to provide evidence of his claims. June 8 Federal judge Leo Sorokin voids President Trump's $100,000 fee requirement for H-1B visa applications, ruling that Trump lacked congressional authority to impose what amounted to a tax on the programme. The Kennedy Center removes Donald Trump's name from the building following the ruling. A U.S.
== Hydrogen-7 == 7H (atomic mass 7.05275(108) Da) has one proton and six neutrons. It was first synthesized in 2003 by a group of Russian, Japanese and French scientists at Riken's Radioactive Isotope Beam Factory by bombarding hydrogen with helium-8 atoms; all six of the helium-8's neutrons were donated to the hydrogen nucleus. The two remaining protons were detected by the "Riken telescope", a device made of several layers of sensors, positioned behind the target of the RI Beam cyclotron. 7H has a half-life of 652(558) ys (6.52(558)×10−22 s).
=== Wartime 1939–1945 === In 1939, a collection of 16 poems and seven of the 20 short stories published by Thomas in magazines since 1934, appeared as The Map of Love. Ten stories in his next book, Portrait of the Artist as a Young Dog (1940), were based less on lavish fantasy than those in The Map of Love and more on real-life romances featuring himself in Wales. Sales of both books were poor, resulting in Thomas living on meagre fees from writing and reviewing. At this time he borrowed heavily from friends and acquaintances. Hounded by creditors, Thomas and his family left Laugharne in July 1940 and moved to the home of critic John Davenport in Marshfield near Chippenham in Gloucestershire. There Thomas collaborated with Davenport on the satire The Death of the King's Canary, though due to fears of libel the work was not published until 1976. At the outset of the Second World War, worried about conscription, Thomas unsuccessfully sought employment in a reserved occupation with the Ministry of Information. However, an "unreliable lung", as he described his chronic condition—coughing sometimes confined him to bed, and he had a history of bringing up blood and mucus—proved to be the grounds for the military authorities to allocate him a C3 category medical exemption which meant that he would be among the last to be called up for service.
A widely cited moment from this period was her display of the WCC's Avalkoppam ("With Her") solidarity banner following a dance performance at the state government's awards ceremony in 2018, which was met with sustained applause.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.